Stock AnalizMadrigal Pharmaceuticals, Inc. MDGL
Biotechnology: Pharmaceutical Preparations · IPO 2007 · data as of November 13, 2026
Madrigal Pharmaceuticals, Inc. (MDGL) is a healthcare company listed in the US with a market value of about $9.9B. In the twelve months to September 30, 2026 it had revenue of $1.4B and net income of -$155M, a net margin of -10.9%.
Its overall Stock Analiz score is 1.0 out of 5 (weak). The strongest part is future growth (3/5); the weakest is value (0/5).
Key numbers: a 5-year average ROIC of -62%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 84% below the current price.
Score: 1.0 / 5
Checks passed
- Revenue growth above 10% last year
- Profit margin improving
- Strong R&D investment or growth above 20%
- More cash than debt, or low debt to equity
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- 3-year revenue growth above 10% a year
- 3-year free cash flow growth above 10% a year
- 5-year EPS growth above 10% a year
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.4B | $958M | $180M | $0 | $0 | $0 | $0 | $0 | $0 | $0 | — |
| Net income | -$155M | -$288M | -$466M | -$374M | -$295M | -$242M | -$202M | -$84M | -$33M | -$31M | -$26M |
| Free cash flow | -$169M | -$190M | -$457M | -$326M | -$225M | -$184M | -$158M | -$42M | -$26M | -$22M | -$18M |
| EPS (diluted) | $-5.74 | $-12.85 | $-21.90 | $-19.99 | $-17.23 | $-14.63 | $-13.09 | $-5.45 | $-2.22 | $-2.54 | $-5.07 |
| Net margin | -10.9% | -30.1% | -258.6% | — | — | — | — | — | — | — | — |
| ROIC | — | -24.9% | -45.0% | -57.5% | -86.7% | -97.3% | -67.8% | -18.0% | -6.7% | -13.9% | -54.7% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 18 analysts is $688.94, 61% above the current price; targets range from $479.00 to $962.00; the consensus rating is “Strong buy”; expected EPS is $-2.00 for the fiscal year ending December 31, 2026.
Frequently asked questions
Is Madrigal Pharmaceuticals stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 84% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Madrigal Pharmaceuticals pay a dividend?
Not currently.
Is Madrigal Pharmaceuticals a good stock to buy?
We do not give buy or sell advice. Madrigal Pharmaceuticals scores 1.0 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.